A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies

Summary

This is a Phase I study which will analyze any food-drug effects as well as QTc effects of perifosine. Safety and efficacy will also be evaluated. Patients who complete the first 24 days on single agent perifosine may have the opportunity to 1) continue on single agent perifosine; 2) switch to the combination of capecitabine + perifosine; or 3) switch to the combination of sorafenib + perifosine.

Timeline

Start

2012-01-24

Primary completion

2013-11-04

Completion

2013-11-04

Drugs

Indications